1. Market Research
  2. > Pathology
Customer Support

Talk to Ahmad

+1 718 618 4302

Publishers

  • All
    • GlobalData
About 1900 reports for Lymphoma (page 1)

Purchase Reports From Reputable Market Research Publishers

Hodgkin’s Lymphoma - Opportunity Analysis and Forecasts to 2029

  • $ 10995
  • June 2020
  • 140 pages

M. (2019) CANCER, LYMPHOMA, HODGKIN, STATPEARLS.

  • Cancer
  • Chemotherapy
  • Lymphoma
  • Therapy
  • Forecast

Prostate Cancer: Global Drug Forecast and Market Analysis to 2028

  • $ 10995
  • August 2019
  • 212 pages

BAY-##, AN ORAL ATR INHIBITOR, IS BEING INVESTIGATED IN A PHASE I STUDY (BAYER, NCT##) IN SOLID TUMORS (INCLUDING PCA) AND LYMPHOMAS.

  • Cancer
  • Hospital
  • Lymphoma
  • Prostate Cancer
  • Therapy

Transthyretin Amyloidosis - Global Drug Forecast and Market Analysis to 2029

  • $ 10995
  • June 2020
  • 129 pages

AMYLOIDOSIS MAY APPEAR IN CONJUNCTION WITH OR AS A RESULT OF THE FOLLOWING DISORDERS: MULTIPLE MYELOMA, HODGKIN' S LYMPHOMA, LYMPHOMA, MEDULLARY CARCINOMA OF THE THYROID, WHIPPLE DISEASE, CROHN' S DISEASE, OSTEOMYELITIS, RHEUMATOID ARTHRITIS, ANKYLOSING SPONDYLITIS, REITER NATIONAL

  • Antimalarials
  • Endocrine Disease
  • Lymphoma
  • Pathology
  • Pfizer Inc.

Multiple Myeloma: Epidemiology Forecast to 2027

  • $ 3995
  • March 2019
  • 42 pages

The Leukemia and Lymphoma Society (2015) Myeloma.

  • Cancer
  • Lymphoma
  • Japan
  • United States
  • Forecast

Chronic Lymphocytic Leukemia - Competitive Landscape to 2030

  • $ 3495
  • May 2020
  • 55 pages

Lung Cancer Breast Cancer Leukemia Lymphoma Non-Small Cell Lung...

  • Leukemia
  • Lymphoma
  • AbbVie Inc.
  • AstraZeneca PLC
  • Roche Group

Systemic Lupus Erythematosus and Lupus Nephritis: Global Drug Forecast and Market Analysis to 2027

  • $ 10995
  • February 2020
  • 163 pages

R. (2016) ' B CELLS GONE ROGUE: THE INTERSECTION OF DIFFUSE LARGE B CELL LYMPHOMA AND AUTOIMMUNE DISEASE', EXPERT REVIEW OF HEMATOLOGY, ##(##), PP. ##-##.

  • Genitourinary System Disease
  • Hospital
  • Lymphoma
  • Musculoskeletal Disorder
  • Therapy

Burkitt Lymphoma Global Clinical Trials Review, H1, 2020

  • $ 2500
  • February 2020
  • 311 pages

Burkitt Lymphoma Global Clinical Trials Review, H##, 2020 H e a l t h c a r e H e a l t h c a r e REFERENCE CODE: GDHC##CTIDB PUBLICATION DATE: FEB 2020 LIST OF TABLES LIST OF FIGURES Burkitt Lymphoma Global Clinical Trials Review, H##, 2020 outlines clinical trials in Burkitt

  • Clinical Trial
  • Immunotherapy
  • Lymphoma
  • Monoclonal Antibody
  • Therapy

B-Cell Non-Hodgkin’s Lymphoma (NHL): Opportunity Analysis and Forecasts to 2027

  • $ 10995
  • June 2019
  • 147 pages

The faster-growing, more aggressive B-cell lymphomas are referred to as high-grade lymphomas, and include DLBCL, MCL, primary mediastinal large B-cell lymphoma, follicular large-cell lymphoma, and intravascular large B-cell lymphoma.

  • Cancer
  • Immunotherapy
  • Lymphoma
  • Therapy
  • United States

B-Cell Non-Hodgkin’s Lymphoma: Epidemiology Forecast to 2027

  • $ 3995
  • June 2019
  • 44 pages

In Japan, data on malignant lymphoma encompasses all type of lymphoma (CIS, NCC, 2018).

  • Cancer
  • Immunotherapy
  • Lymphoma
  • Pathology
  • United States

Multiple Myeloma: Global Drug Forecast and Market Analysis to 2027

  • $ 10995
  • March 2019
  • 164 pages

THE LEUKEMIA AND LYMPHOMA SOCIETY (2015) MYELOMA.

  • Cancer
  • Cancer Hormonal Therapy
  • Lymphoma
  • Pathology
  • Therapy

Colorectal Cancer: Global Drug Forecast and Market Analysis to 2028

  • $ 10995
  • April 2020
  • 153 pages

FRANCE AND GERMANY ITALY SPAIN TO DETERMINE THE DISTRIBUTION OF DIAGNOSED INCIDENT CASES OF CRC BY STAGE AT DIAGNOSIS IN SPAIN, A RETROSPECTIVE FOLLOW-UP STUDY OF INDIVIDUALS DIAGNOSED WITH CRC (EXCLUDING CASES WITH DEATH CERTIFICATE-ONLY INFORMATION AND LYMPHOMAS) DURING 2006-2011 WAS USED

  • Colorectal Cancer
  • Lymphoma
  • Targeted Therapy
  • Therapy
  • Merck & Co., Inc.

Cutaneous B-Cell Lymphoma Global Clinical Trials Review, H1, 2019

  • $ 2500
  • April 2019
  • 63 pages

Cutaneous B-Cell Lymphoma clinical trial report consists of ## trials.

  • Cancer
  • Immunotherapy
  • Lymphoma
  • Monoclonal Antibody
  • Pathology

Brain Cancer: Epidemiology Forecast to 2027

  • $ 3995
  • October 2018
  • 32 pages

Brain Cancer: Epidemiology Forecast to 2027 Summary Epidemiologists forecast that the diagnosed incident cases of brain cancer will increase from 119,717 cases in 2017 to 151,067 cases in 2027, at an ...

  • Brain Cancer
  • Cancer
  • Lymphoma
  • Pathology
  • Forecast

Diffuse Large B-Cell Lymphoma Global Clinical Trials Review, H1, 2019

  • $ 2500
  • May 2019
  • 1115 pages

Diffuse Large B-Cell Lymphoma Global Clinical Trials Review, H##, 2019 List of Tables List of Figures Report Guidance GlobalData Clinical Trials Report Coverage Clinical Trials by Region Clinical Trials and Average Enrollment by Country Top Five Countries Contributing to Clinical Trials in A

  • Clinical Trial
  • Lymphoma
  • Pharmaceutical
  • Therapy
  • World

Multiple Sclerosis - Global Drug Forecast and Market Analysis to 2028

  • $ 10995
  • December 2019
  • 356 pages

IN ADDITION, THERE WERE SEVERAL CASES OF MALIGNANCY IN LEMTRADA-TREATED PATIENTS, INCLUDING NON-EBV-ASSOCIATED BURKITT LYMPHOMA, BREAST CANCER, AND CERVICAL CARCINOMA.

  • Lymphoma
  • Monoclonal Antibody
  • Therapy
  • United States
  • Biogen Idec Inc.

Hepatocellular Carcinoma: Competitive Landscape to 2026

  • $ 3495
  • November 2018
  • 50 pages

Other oncology trials: ##% Ovarian Cancer NUMBER OF CLINICAL TRIALS ##, ## ##, ## ##, ## ##, ## ##, ## ##, ## ##, ## ##, ## ##, ## ##, ## Lymphoma Solid Tumor HCC: ##% Source: GlobalData, Pharma Intelligence Center [Accessed September 2018] Ovarian Cancer Multiple Myeloma Acute Myelocytic Leukemia Pro

  • Clinical Trial
  • Hepatitis
  • Lymphoma
  • Eli Lilly & Co.
  • Merck & Co., Inc.

Regenerative Medicine - Thematic Research

  • $ 1950
  • November 2019
  • 24 pages

Yescarta is a CAR-T therapy indicated for patients with certain types of B-cell lymphoma.

  • Lymphoma
  • Regenerative Medicine
  • DiscGenics, Inc.
  • Vericel Corporation
  • ViaCyte, Inc.

Prostate Cancer: Epidemiology Forecast to 2028

  • $ 3995
  • August 2019
  • 48 pages

National Cancer Institute, 2019b Ethnicity TABLE ##: RISK FACTORS AND COMORBIDITIES FOR PROSTATE CANCER Prior malignancies Prior malignancies and current cancers, such as lymphoma, leukemia, and metastatic cancers, are often observed in men with prostate cancer.

  • Cancer
  • Lymphoma
  • Prostate Cancer
  • Japan
  • United States

Age-Related Macular Degeneration: Global Drug Forecast and Market Analysis to 2028

  • $ 10995
  • April 2020
  • 204 pages

Age-Related Macular Degeneration: Global Drug Forecast and Market Analysis to 2028 Summary Age-related macular degeneration (AMD) is an eye condition that is characterized by the gradual deterioration ...

  • Lymphoma
  • Monoclonal Antibody
  • Ophthalmology
  • Targeted Therapy
  • Therapy

Human T-Lymphotropic Virus (HTLV) Tests (In Vitro Diagnostics) - Global Market Analysis and Forecast Model (COVID-19 market impact)

  • $ 7500
  • June 2020
  • 1 pages

Human T-Lymphotropic Virus (HTLV) testing is often performed in patients with lymphomas or T cell disorders as part of ATLL diagnosis.

  • Diagnostics
  • In Vitro Diagnostics
  • Lymphoma
  • Medical Biotechnology
  • Supply
View report >

Lymphoma Statistics in the UK

  • January 2018
  • 6 pages

(observed and ##. ##% five years from a lymphoma diagnosis in 2009-2013.

  • Cancer
  • Lymphoma
  • United Kingdom
  • Demographic

Lymphoma Statistics December 2019

Lymphoma Statistics December 2019

Lymphoma Statistics December 2019

Lymphoma Statistics December 2019

Lymphoma Statistics December 2019

Reportlinker.com © Copyright 2020. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on